Clinical Trials
20 trialsNCT05311618 2024-04-01
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
Phase 1 Unknown
NCT04670445 2023-10-23
UPLIFT
Massachusetts General Hospital
Phase NA Unknown
NCT05708950 2023-07-13
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
Phase 1/2 Unknown
NCT05223218 2023-07-03
Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study
Namida Lab
Unknown
NCT04631731 2023-06-01
ICEMELT
Western Sydney Local Health District
Phase 1/2 Unknown
NCT03634982 2022-09-01
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Unknown
NCT03934827 2022-08-11
MICROBIOME
Imperial College London
Phase 1 Unknown
NCT05230186 2022-02-09
A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
TScan Therapeutics, Inc.
Unknown
NCT05180851 2022-02-01
YSCH-01
Shanghai Fengxian District Central Hospital
Phase EARLY_PHASE1 Unknown
NCT04695015 2021-01-05
Research of Pathological Imaging Diagnosis of Ocular Tumors Based on New Artificial Intelligence Algorithm
Peking University
Unknown
NCT03896958 2020-12-04
PIONEER
SpeciCare
Unknown
NCT03544723 2020-06-09
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Phase 2 Unknown
NCT03638206 2019-12-11
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
Phase 1/2 Unknown
NCT03517332 2018-11-20
Circulating Tumor DNA Exposure in Peripheral Blood
Quantgene Inc.
Unknown
NCT02366546 2018-10-24
Investigator Initiated Phase 1 Study of TBI-1301
Mie University
Phase 1 Unknown
NCT03285230 2017-09-19
E3N
Institut National de la Santé Et de la Recherche Médicale, France
Unknown
NCT02457650 2016-08-03
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies
Shenzhen Second People's Hospital
Phase 1 Unknown
NCT00553683 2014-01-14
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
Rutgers, The State University of New Jersey
Phase 1/2 Unknown
NCT01584115 2012-04-25
Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)
Instituto de Investigação em Imunologia
Phase 1/2 Unknown
NCT00108875 2006-07-28
Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer
Julius-Maximilians University
Phase 1/2 Unknown